Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Superior neutralizing response after first versus second SARS‐CoV‐2 infection in fully vaccinated individuals

dc.contributor.authorRivas Hernández, Gonzalo
dc.contributor.authorLabiod Becerro, Nuria
dc.contributor.authorLuczkowiak, Joanna
dc.contributor.authorLasala Sánchez, Fátima
dc.contributor.authorRolo, Marta
dc.contributor.authorMancheño Losa, Mikel
dc.contributor.authorRial Crestelo, David
dc.contributor.authorLora-Tamayo Morillo-Velarde, Jaime
dc.contributor.authorPérez Rivilla, José Alfredo
dc.contributor.authorFolgueira López, María Dolores
dc.contributor.authorDelgado Vázquez, Rafael
dc.date.accessioned2024-04-22T07:18:38Z
dc.date.available2024-04-22T07:18:38Z
dc.date.issued2023-11
dc.description.abstractCurrently, the majority of the population has been vaccinated against COVID‐19and/or has experienced SARS‐CoV‐2 infection either before or after vaccination.The immunological response to repeated episodes of infections is not completelyclear. We measured SARS‐CoV‐2 specific neutralization titers by a pseudovirusassay after BA.1 infection and RBD‐specific immunoglobulin G (IgG), immuno-globulin A (IgA), and immunoglobulin M (IgM) in a cohort of COVID‐19uninfected and triple vaccinated individuals (breakthrough infection group,BTI) as compared with those previously infected by SARS‐CoV‐2 (reinfectiongroup, REI) who underwent identical vaccination schedule. SARS‐CoV‐2specificneutralizing response after BA.1 infection was significantly higher in the BTIgroup as compared with the REI. Furthermore, neutralization titers in REI werenot significant different from convalescent non reinfected controls. RBD‐specific IgG and IgA, but not IgM, werealso significantly higher in BTI ascompared with REI. Our results show that the first episode of SARS‐CoV‐2infection induces a significant increase inneutralizing titers in triple vaccinatedindividuals and that previous SARS‐CoV‐2 infection compromise significantly theneutralization response induced by reinfection, even by divergent SARS‐CoV‐2variants and at least up to 2 years postinfection, suggesting a fundamentallimitation in inducing effective booster through the intranasal route in previouslyinfected individuals
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.fundingtypeAPC financiada por la UCM
dc.description.refereedTRUE
dc.description.sponsorshipEuropean Commission
dc.description.sponsorshipComunidad de Madrid
dc.description.sponsorshipInstituto de Salud Carlos III (España)
dc.description.sponsorshipCentro de Investigación Biomédica en Red
dc.description.sponsorshipFundación Caixa‐Health Research
dc.description.statuspub
dc.identifier.citationRivas G, Labiod N, Luczkowiak J, Lasala F, Rolo M, Mancheño-Losa M, Rial-Crestelo D, Lora-Tamayo J, Pérez-Rivilla A, Folgueira MD, Delgado R. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals. J Med Virol. 2023 Nov;95(11):e29225. doi: 10.1002/jmv.29225
dc.identifier.doi10.1002/jmv.29225
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.officialurlhttps://doi.org/10.1002/jmv.29225
dc.identifier.pmid37971751
dc.identifier.relatedurlhttps://onlinelibrary.wiley.com/doi/10.1002/jmv.29225
dc.identifier.urihttps://hdl.handle.net/20.500.14352/103291
dc.issue.number11
dc.journal.titleJournal of Medical Virology
dc.language.isoeng
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/HE/101046084
dc.relation.projectIDP2022/BMD‐7274
dc.relation.projectIDISCIII/FIS/PI2100989
dc.relation.projectIDProject Stop Ebola HR18‐00469
dc.relation.projectIDPAII62/21‐ANTICIPA/2021‐23
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu616.9
dc.subject.keywordCoronavirus
dc.subject.keywordHumoral immunity
dc.subject.keywordNeutralization
dc.subject.keywordReinfection
dc.subject.keywordSARS coronavirus
dc.subject.keywordVaccines/vaccine strains
dc.subject.ucmEnfermedades infecciosas
dc.subject.unesco3205.05 Enfermedades Infecciosas
dc.titleSuperior neutralizing response after first versus second SARS‐CoV‐2 infection in fully vaccinated individuals
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number95
dspace.entity.typePublication
relation.isAuthorOfPublication1f7ba99e-b586-4ff0-9bcd-83e6a91729e4
relation.isAuthorOfPublicationc7667657-f914-4b7b-af19-64a705bc0ccd
relation.isAuthorOfPublicatione60f9b15-34c9-4353-a672-54926c89eec4
relation.isAuthorOfPublication6612f6f9-e6aa-4eb2-bcf2-158a46babc21
relation.isAuthorOfPublication.latestForDiscovery1f7ba99e-b586-4ff0-9bcd-83e6a91729e4

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Rivas-2023-Superior-neutralizing-response-afte.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format

Collections